Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no ...

PBMs are putting weight loss drugs, including Wegovy and Zepbound, on their national formularies, but coverage by plans is ...

The FDA, in a stark reversal, on Friday said it would reconsider its decision to remove Eli Lilly’s tirzepatide from its ...

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Rival manufacturers fight for the right to sell weight loss drugsThere’s a new fight brewing between ...

The U.S. Food and Drug Administration on Friday agreed to reconsider its recent decision barring drug compounders from ...

Peptide companies' are creating knock-off versions of these drugs that have not been approved by the FDA and contain ...

Health-care costs are going up and and yet, workers may still not get the coverage they want — particularly when it comes to drugs like Ozempic.

Some patients fear that they’ll lose access to tirzepatide because the US Food and Drug Administration determined that a ...

Popular weight loss drugs are so pricey that many may shell out hundreds or even thousands of dollars on them. Some ...

There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.

The surge in popularity of drugs like Ozempic, driven in part by its weight loss benefits, is contributing to a record-high ...